Cosmo Pharmaceuticals N.V - Asset Resilience Ratio

Latest as of December 2025: 10.92%

Cosmo Pharmaceuticals N.V (C43) has an Asset Resilience Ratio of 10.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Cosmo Pharmaceuticals N.V to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€66.89 Million

≈ $78.21 Million USD Cash + Short-term Investments

Total Assets

€612.64 Million

≈ $716.24 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Cosmo Pharmaceuticals N.V's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cosmo Pharmaceuticals N.V total assets.

Liquid Assets Composition Over Time

This chart breaks down Cosmo Pharmaceuticals N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read C43 total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€66.89 Million	10.92%
Total Liquid Assets	€66.89 Million	10.92%

Asset Resilience Insights

Moderate Liquidity: Cosmo Pharmaceuticals N.V has 10.92% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Cosmo Pharmaceuticals N.V Industry Peers by Asset Resilience Ratio

Compare Cosmo Pharmaceuticals N.V's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Pfizer Inc NYSE:PFE	Drug Manufacturers - General	5.33%
AbbVie Inc NYSE:ABBV	Drug Manufacturers - General	0.02%
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	0.22%
AstraZeneca PLC MX:AZNN	Drug Manufacturers - General	0.03%
Novartis AG ADR NYSE:NVS	Drug Manufacturers - General	0.06%
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd SHE:300357	Drug Manufacturers - General	9.91%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%
Eli Lilly and Company SA:LILY34	Drug Manufacturers - General	6.46%

Annual Asset Resilience Ratio for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Cosmo Pharmaceuticals N.V.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.92%	€66.89 Million ≈ $78.21 Million	€612.64 Million ≈ $716.24 Million	-4.34pp
2024-12-31	15.26%	€98.67 Million ≈ $115.35 Million	€646.77 Million ≈ $756.14 Million	+8.00pp
2022-12-31	7.26%	€55.13 Million ≈ $64.45 Million	€759.59 Million ≈ $888.04 Million	+4.32pp
2021-12-31	2.94%	€23.65 Million ≈ $27.65 Million	€805.56 Million ≈ $941.79 Million	-1.58pp
2020-12-31	4.51%	€26.91 Million ≈ $31.47 Million	€596.16 Million ≈ $696.97 Million	-22.46pp
2019-12-31	26.97%	€157.82 Million ≈ $184.51 Million	€585.16 Million ≈ $684.11 Million	+4.80pp
2018-12-31	22.18%	€138.75 Million ≈ $162.21 Million	€625.69 Million ≈ $731.49 Million	+16.60pp
2017-12-31	5.57%	€27.76 Million ≈ $32.45 Million	€497.97 Million ≈ $582.18 Million	-5.44pp
2016-12-31	11.01%	€48.84 Million ≈ $57.09 Million	€443.47 Million ≈ $518.47 Million	--

pp = percentage points

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.11 Billion

€950.63 Million EUR

Market Cap Rank

#8977 Global

#1150 in Germany

Share Price

€55.30

Change (1 day)

+0.18%

52-Week Range

€54.90 - €139.00

All Time High

€153.25